P0051: Is NKCC1, a marker of dysplasia associated with inflammation and CAC, playing a role in colorectal carcinogenesis?ECCO'25Year: 2025
Authors: Adam, P.(1)*;Salée, C.(1);Stepniak , M.(1);Loly, J.P.(2);Vieujean, S.(1,2,3);Reenaers , C.(2);Coimbra, C.(4);Decker, E.(4);Massot, C.(1,2);Delvenne, P.(5);Louis, E.(1,2);Meuwis, M.A.(1,2);
(1)GIGA institute Uliège, Laboratory of Translational Gastroenterology, Liège, Belgium;(2)CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;(3)INFINY Institute, Department of Gastroenterology INSERM NGERE, Nancy, France;(4)CHU of Liège, Abdominal- endocrine and transplantation, Liège, Belgium;(5)CHU of Liège, Pathological Anatomy and Cytology, Liège, Belgium;
1. Fantini MC, Guadagni I. From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies. Dig Liver Dis. 2021;53(5):558-565. doi:10.1016/j.dld.2021.01.012
2. Merli AM, Vieujean S, Massot C, et al. Solute Carrier Family 12 Member 2 as a Proteomic and Histological Biomarker of Dysplasia and Neoplasia in Ulcerative Colitis. J Crohn’s Colitis. 2021;15(2):287-298. doi:10.1093/ecco-jcc/jjaa168
3. Koumangoye R, Omer S, Kabeer MH, Delpire E. Novel Human NKCC1 Mutations Cause Defects in Goblet Cell Mucus Secretion and Chronic Inflammation. Cmgh. 2020;9(2):239-255. doi:10.1016/j.jcmgh.2019.10.006
4. Pelka K, Hofree M, Chen JH, et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell. 2021;184(18):4734-4752.e20. doi:10.1016/j.cell.2021.08.003
P0053: Microscopic colitis: analysis of microbiota changes in different segments of the colon and terminal ileum.ECCO'25Year: 2025
Authors: Kiudelis, V.(1,2)*;Alzbutas, G.(2);Karaliute, I.(2);Lukosevicius, R.(2);Berneriene, N.(2);Skieceviciene, J.(2);Kupcinskas, J.(1,2);
(1)Lithuanian University of Health Sciences, Department of Gastroenterology, Kaunas, Lithuania;(2)Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania;
1.Verhaegh BPM, Münch A, Guagnozzi D, et al. Course of Disease in Patients with Microscopic Colitis: A European Prospective Incident Cohort Study. J Crohns Colitis. 2021;15(7):1174-1183.
2.Miehlke S, Guagnozzi D, Zabana Y, et al. European guidelines on microscopic colitis: United European Gastroenterology (UEG) and European Microscopic Colitis Group (EMCG) statements and recommendations. United European Gastroenterol J. Published online 2020.
3.Burke KE, D’Amato M, Ng SC, Pardi DS, Ludvigsson JF, Khalili H. Microscopic colitis. Nat Rev Dis Primers. 2021;7(1).
P0054: Human colonoid-derived monolayers and Caco-2: comparative analysis of inflammatory responsesECCO'25Year: 2025
Authors: Chiara, M.L.(1)*;Parente, I.A.(1);Flammini, L.(1);Martina, V.(1);Vacondio, F.(1);Federica, G.(2);de’Angelis, G.L.(2);Elisabetta, B.(1);Bertoni, S.(1);
(1)University of Parma, Food and Drug Department, Parma, Italy;(2)University of Parma, Medicine and Surgery Department, Parma, Italy;
P0055: Impact of Indole-3-Propionic Acid on Bacterial Invasion Potential of Klebsiella Strains Isolated from Pediatric Ulcerative Colitis PatientsECCO'25Year: 2025
Authors: Arjomand Fard, N.(1)*;Aujla, H.(2);Stuart, L.(1);C Cheng, C.(2);Elhenawy, W.(3);Perry, T.(4);Wine, E.(5);
(1)University of Alberta, Department of Physiology, Edmonton, Canada;(2)University of Alberta, Department of Pediatrics, Edmonton, Canada;(3)University of Alberta, Department of Medical Microbiology & Immunology, Edmonton, Canada;(4)University of Alberta, Department of Surgery, Edmonton, Canada;(5)University of Alberta, Department of Pediatrics and Physiology, Edmonton, Canada;
1. Ghiboub M, Verburgt CM, Sovran B, Benninga MA, de Jonge WJ, Van Limbergen JE. Nutritional therapy to modulate tryptophan metabolism and aryl hydrocarbon-receptor signaling activation in human diseases. Nutrients. 2020 Sep 17;12(9):2846.
2. Flannigan KL, Nieves KM, Szczepanski HE, Serra A, Lee JW, Alston LA, Ramay H, Mani S, Hirota SA. The pregnane X receptor and indole-3-propionic acid shape the intestinal mesenchyme to restrain inflammation and fibrosis. Cellular and molecular gastroenterology and hepatology. 2023 Jan 1;15(3):765-95.
3. Fu Y, Gao H, Hou X, Chen Y, Xu K. Pretreatment with IPA ameliorates colitis in mice: Colon transcriptome and fecal 16S amplicon profiling. Frontiers in Immunology. 2022 Sep 8;13:1014881.
P0056: Efficacy of Infliximab in Biologic-Experienced Patients with Inflammatory Bowel Disease: A Retrospective StudyECCO'25Year: 2025
Authors: Borges Chaves, C.(1)*;Corveira, J.(2);Ferreira, A.M.(3);Lopes, S.(3);Mendes, S.(3);Ferreira, M.(3);Narra Figueiredo, P.(1,2);Portela, F.(2,3);
(1)Local Health Unit of Coimbra, Gastroenterology Department, Coimbra, Portugal;(2)University of Coimbra, Faculty of Medicine, Coimbra, Portugal;(3)Local Health Unit of Coimbra, IBD Unit- Gastroenterology Department, Coimbra, Portugal;
1. Grillo, S., Mezzina, N., Landi, S., Massari, A., Grassi, E., Dell’Era, A., & Ardizzone, S. (2018). P.07.22 Anti-TNF-Alfa Second-Line Infliximab Therapy in Patients Affected by Crohn’s Disease and Ulcerative Colitis: Who and How Recovers Remission? Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology (SIGE) and of the Italian Association for the Study of the Liver (AISF), 50(2).
2. Russo E, Hackett R, Campbell S, et alPWE-071 Efficacy Of Infliximab As Second-line Biologic In Crohn’s DiseaseGut 2014;63:A154-A155.
P0058: Modulation of early innate and adaptive immune responses in primary human intestinal tissue ex vivoECCO'25Year: 2025
Authors: Beneke, V.(1)*;Grieger, K.(1);Dehmel, S.(1);Neuhaus, V.(1);Linge, H.(2);Kulik, U.(2);Aselmann, H.(3);Gundert, B.(3);Braun, A.(1);Hesse, C.(1);Sewald, K.(1);
(1)Fraunhofer ITEM, Preclinical Pharmacology and Toxicology, Hannover, Germany;(2)Hannover Medical School MHH, Department of General- Visceral and Transplant Surgery, Hannover, Germany;(3)KRH clinics Hannover, Department of General- Visceral and Minimally Invasive Surgery, Hannover, Germany;
P0059: Mechanistic understanding of MB310: a consortium of gut commensal bacteria for the treatment of Ulcerative ColitisECCO'25Year: 2025
Authors: Schreiber, F.(1)*;Villemin, C.(1);Sharpington, T.(2);Lawley, T.D.(2,3);Robinson , M.J.(4);Bakdash, G.(1);
(1)Microbiotica Ltd, Translational Biology, Cambridge, United Kingdom;(2)Microbiotica. Ltd, Microbiotica, Cambridge, United Kingdom;(3)Wellcome Sanger Institute, Host-Microbiota Interactions, Cambridge, United Kingdom;(4)Microbiotica Ltd, Discovery, Cambridge, United Kingdom;
P0060: GPR15L counteracts chronic colitis by shaping the intestinal microbiotaECCO'25Year: 2025
Authors: Leggio, M.(1);Schramm, S.(1);Ocón, B.(2);Wirtz, S.(1);Puertolas Balint, F.(3);Dietz, L.(1);Schröder, B.(3);Butcher, E.(2);Müller, T.(1);Neurath, M.F.(1);Zundler, S.(1)*;
(1)University Hospital Erlangen, Department of Medicine 1, Erlangen, Germany;(2)Stanford University School of Medicine, Department of Pathology, Stanford, United States;(3)Umeå University, Department of Molecular Biology, Umeå, Sweden;
P0061: Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction studyECCO'25Year: 2025
Authors: Sridhar, S.(1)*;Hart, A.(1);Venkat, S.(1);Huang, K.H.G.(1);Yarandi, S.(1);Germinaro, M.(1);Vetter, M.(1);Rubin, D.T.(2);Dignass, A.(3);Cua, D.(1);Freeman, T.(1);Waterworth, D.(1);McRae, B.(1);Verstockt, B.(4);Branigan, P.(1);
(1)Janssen Research & Development LLC, Research & Development, Spring House, United States;(2)University of Chicago Medicine- Inflammatory Bowel Disease Center, Medical, Chicago, United States;(3)Department of Medicine I, Agaplesion Markus Hospital- Goethe University, Frankfurt, Germany;(4)Department of Gastroenterology and Hepatology, University Hospitals Leuven- and Translational Research in Gastrointestinal Disorders- Department of Chronic Disease- Metabolism, Leuven, Belgium;
1. Atreya R, Abreu MT, Krueger JG, et al. P165 Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling. Journal of Crohn's and Colitis. 2024;18(Supplement_1):i470-i470. doi:10.1093/ecco-jcc/jjad212.0295
2. The Efficacy and Safety of Guselkumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Maintenance Study. Gastroenterol Hepatol (N Y). Jul 2024;20(7 Suppl 6):8-9.
3. Peyrin-Biroulet L, Allegretti JR, Rubin DT, et al. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology. Sep 1 2023;doi:10.1053/j.gastro.2023.08.038
4. Sridhar S, Hart A, Venkat S, et al. OP23 Guselkumab induction restores intestinal immune homeostasis and promotes epithelial repair in moderately to severely active Ulcerative Colitis. Journal of Crohn's and Colitis. 2024;18(Supplement_1):i41-i41. doi:10.1093/ecco-jcc/jjad212.0023
P0062: Circulating immune cell populations as predictive markers of vedolizumab response in Crohn diseaseECCO'25Year: 2025
Authors: Soleto, I.(1)*;González-de Castro, C.(2); Arribas, E.(3);Ramirez, C.(4);Baldan-Martin, M.(4); Riestra, S.(5); Lucendo, A.J.(6); García, M.J.(7); Martín-Arranz, E.(8);De Prado, Á.(3);Casanova, M.J.(4);Chaparro, M.(4);Bernardo*, D.(3);Gisbert*, J.P.(4);
(1)$Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Inflammatory Bowel Disease Unit, Madrid, Spain;(2)$Unidad de Excelencia Instituto de Biomedicina y Genética Molecular IBGM- Universidad de Valladolid-CISC and Centro de Investigación Biomédica en Red de Enfermedades Infecciosas CIBERINFEC, Mucosal Immunology Lab, Valladolid, Spain;(3)Unidad de Excelencia Instituto de Biomedicina y Genética Molecular IBGM- Universidad de Valladolid-CISC and Centro de Investigación Biomédica en Red de Enfermedades Infecciosas CIBERINFEC, Mucosal Immunology Lab, Valladolid, Spain;(4)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Inflammatory Bowel Disease Unit, Madrid, Spain;(5)Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(6)Hospital General de Tomelloso- Instituto de Investigación Sanitaria de Castilla-La Mancha IDISCAM- CIBEREHD, Gastroenterology Unit, Ciudad Real, Spain;(7)Hospital Universitario Marqués de Valdecilla and IDIVAL, Gastroenterology and Hepatology Unit, Santander, Spain;(8)Hospital Universitario La Paz and Instituto de Investigación Sanitaria La Paz IdiPaz, Gastroenterology Unit, Madrid, Spain; *Authors share co-senior authorship. $ These authors contributed equally to this work
P0063: Prevalence of sarcopenia in a cohort of patients with inflammatory bowel disease: observational study in a tertiary care centreECCO'25Year: 2025
Authors: Palmisano, C.M.(1)*;Dell'Aquila, P.(2);Cormio, S.(3);Boraccino, V.(4);Novielli, D.(4);Savino, F.(4);Squeo, F.(4);Forastiere, D.(4);Moschetta, A.(5);Principi, M.R.D.(6);
(1)University of Bari "Aldo Moro", Internal Medicine Unit "C. Frugoni" Department of Interdisciplinary Medicine-, Bari, Italy;(2)University of Bari, Department of Precision and Regenerative Medicine and Ionian Area, Bari, Italy;(3)University of Bari, Section of Gastroenterology- Department of Precision and Regenerative Medicine and Ionian Area-, Bari, Italy;(4)University of Bari, Section of Gastroenterology- Department of Precision and Regenerative Medicine and Ionian Area, Bari, Italy;(5)University of Bari, Department of Interdisciplinary Medicine- University of Bari "Aldo Moro", Bari, Italy;(6)University of Bari, 3 Section of Gastroenterology- Department of Precision and Regenerative Medicine and Ionian Area-, Bari, Italy;
2. L.-K. Chen, L.-K. Liu, J. Woo, P. Assantachai, T.-W. Auyeung, K.S. Bahyah, et al. Sarcopenia in Asia: consensus report of the Asian working group for sarcopenia J Am Med Dir Assoc, 15 (2) (2014), pp. 95-101
3. RA Fielding, B. Vellas, WJ Evans, S. Bhasin, JE Morley, AB Newman, et al. Sarcopenia: una condizione non diagnosticata negli anziani. Definizione di consenso attuale: prevalenza, eziologia e conseguenze. Gruppo di lavoro internazionale sulla sarcopenia J Am Med Dir Assoc, 12 (4) (2011), pagg. 249-256
P0064: Investigating a pathogenic role for IL-18 in Inflammatory Bowel Disease beyond the classical type 1 immunity paradigmECCO'25Year: 2025
Authors: Grillmaier, M.(1)*;Barendregt, D.(1);Calado, B.(1);Heredia, M.(1);Smits, W.(1);Tuk, B.(1);van Berkel, L.(1);Hulleman-van Haaften, D.(1);Klomberg, R.(2);Vuijk, S.(2);Camman, A.(2);Doukas, M.(3);de Ridder, L.(2);Escher, J.(2);Samsom, J.(1);
(1)Erasmus University Medical Center - Sophia Children's Hospital, Laboratory of Pediatrics, Rotterdam, The Netherlands;(2)Erasmus University Medical Center - Sophia Children's Hospital, Pediatric Gastroenterology, Rotterdam, The Netherlands;(3)Erasmus University Medical Center, Pathology, Rotterdam, The Netherlands;
P0065: Circulating cell-free DNA and mitochondrial DNA differentiate disease activity in paediatric-onset inflammatory bowel disease: Interim analysis from Scotland-wide Mini-MUSIC study (2020-26)ECCO'25Year: 2025
Authors: Wands, D.(1,2,3)*;Lau, S.Y.(2);Chuah, C.S.(2);Hall, R.(2);Whelan, R.(2);Fischer, L.(2);Kalla, R.(2);Cartlidge, P.(2);Drury, B.(2);Chalmers, I.(4);Hansen, R.(5);Wilson, M.(3);Jones, G.(2);Wilson, D.(3);Ho, G.T.(2);
(1)Royal Hospital For Children, Paediatric Gastroenterology- Hepatology and Nutrition, Glasgow, United Kingdom;(2)University of Edinburgh, Centre for Inflammation Research, Edinburgh, United Kingdom;(3)University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom;(4)Royal Aberdeen Children’s Hospital, Department of Paediatric Gastroenterology- Hepatology and Nutrition, Aberdeen, United Kingdom;(5)University of Dundee, Division of Respiratory Medicine and Gastroenterology, Dundee, United Kingdom;
1. Haberman Y, Karns R, Dexheimer PJ, et al. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun. 2019;10(1):38. doi:10.1038/s41467-018-07841-32.
2. Mottawea W, Chiang C-K, Mühlbauer M, et al. Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn’s disease. Nat Commun. 2016;7:13419. doi:10.1038/ncomms134193.
3. Chuah CS, Fischer L, Ho G-T. Circulating Cell-Free DNA in Inflammatory Bowel Disease: Liquid Biopsies with Mechanistic and Translational Implications. Fac Rev. 2023;12:14. doi:10.12703/r/12-144.
4. Boyapati RK, Dorward DA, Tamborska A, et al. Mitochondrial DNA Is a Pro-Inflammatory Damage-Associated Molecular Pattern Released During Active IBD. Inflamm Bowel Dis. 2018;24(10). doi:10.1093/ibd/izy095
P0066: Enhanced transcription of human endogenous retroviruses and downregulation of TRIM28 in patients with Crohn’s disease and ulcerative colitisECCO'25Year: 2025
Authors: Ribaldone, D.G.(1)*;Bergallo, M.(2);Galliano, I.(2);Veglio, V.(3);Pitoni, D.(3);Caviglia, G.P.(3);Frara, S.(3);Anxhela, P.(3);Tribocco, E.(3);Tovo, P.A.(2);
(1)University of Turin, Department of Mediical Sciences, Turin, Italy;(2)University of Turin, Department of Public Health and Pediatric Sciences, Turin, Italy;(3)University of Turin, Department of Medical Sciences, Turin, Italy;
P0067: Exploring potential therapeutic implication of anti inflammatory drugs and Probiotic in Experimental Models of IBD-dependent SarcopeniaECCO'25Year: 2025
Authors: Troisi , S.(1,2);Rondinone , B.(2);Petito , V.(2);Masi , L.(2);Emoli , V.(2);Deleu , S.(2,3,4);Pane , C.(1,2)*;Distante , S.(4);Lopetuso , L.R.(1,5,6);Gasbarrini , A.(2,4,6);Scaldaferri , F.(2,4,6);
(1)University of Chieti-Pescara ‘G. D’Annunzio’, Center for Advanced Studies and Technology CAST, Chieti, Italy;(2)Fondazione Policlinico Universitario “A. Gemelli”- IRCCS, CeMAD Translational Research Laboratory- Digestive Disease center- Department of Medical and Surgical Sciences, Rome, Italy;(3)KU Leuven, Department of Chronic Diseases & Metabolism CHROMETA, Leuven, Belgium;(4)Catholic University of the Sacred Heart, Department of Translational Medicine and Surgery, Rome, Italy;(5)University of Chieti-Pescara ‘G. D’Annunzio’, Department of Medicine and Ageing Sciences, Chieti, Italy;(6)Fondazione Policlinico Universitario “A. Gemelli” IRCCS, IBD unit- Digestive Disease center- Department of Medical and Surgical Sciences, Rome, Italy;
1. Dhaliwal A, Quinlan JI, Overthrow K, et al. Sarcopenia in Inflammatory Bowel Disease: A Narrative Overview. Nutrients. 2021;13(2):656. Published 2021 Feb 17. doi:10.3390/nu13020656
2. Ehlers L, Bannert K, Rohde S, et al. Preclinical insights into the gut-skeletal muscle axis in chronic gastrointestinal diseases. J Cell Mol Med. 2020;24(15):8304-8314. doi:10.1111/jcmm.15554
3. Neelam PB, Sharma A, Sharma V. Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence. JGH Open. 2024;8(1):e13033. Published 2024 Jan 27. doi:10.1002/jgh3.13033
P0068: Distribution of α4β7 integrin and MAdCAM-1 expression according to the location of intestinal inflammation in a murine model of spontaneous chronic enterocolitisECCO'25Year: 2025
Authors: Martinez Lozano, H.(1)*;Puerto Cantero, M.(2);Ruiz-Martín, C.(3);Miranda-Bautista, J.(1);Marín-Jiménez, I.(1);Menchén Viso, L.(1);
(1)Hospital General Universitario Gregorio Marañón, Gastroenterology, Madrid, Spain;(2)CIBEREHD-IISGM Instituto de Investigación Sanitaria Gregorio Marañón, Gastroenterology, Madrid, Spain;(3)IISGM Instituto de Investigación Sanitaria Gregorio Marañón, Gastroenterology, Madrid, Spain;
P0069: TP-317, a Novel BLT1 Agonist Oral Therapy for Inflammatory Bowel Disease, Exhibits Anti-Inflammatory and Epithelial Barrier Protective Efficacy in Murine DSS Colitis and TNFΔARE IleitisECCO'25Year: 2025
Authors: Verstockt, B.(1)*;Hanley, M.(2);Nakanishi, M.(3);Rosenberg, D.(3);Parkinson, J.(2);Mathias, G.(2);de Zoeten, E.(4);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)Thetis Pharmaceuticals LLC, Medical Affairs, Essex Connecticut, United States;(3)University of Connecticut Health Center, Center for Molecular Medicine, Farmington Connecticut, United States;(4)University of Colorado School of Medicine, Pediatric IBD Center, Aurora Colorado, United States;
1 Jala VR, Maturu P, Bodduluri SR, Krishnan E, Mathis S, Subbarao K, Wang M, Jenson AB, Proctor ML, Rouchka EC, Knight R, Haribabu B. Leukotriene B4-receptor-1 mediated host response shapes gut microbiota and controls colon tumor progression. Oncoimmunology. 2017 Aug 10;6(12):e1361593. PMID 29209564
2 Hayashi S, Muraleedharan CK, Oku M, Tomar S, Hogan SP, Quiros M, Parkos CA, Nusrat A. Intestinal epithelial BLT1 promotes mucosal repair. JCI Insight. 2022 Dec 8;7(23):e162392. PMID 36301666
P0070: Distinct Serum Proteome Alterations Following Vedolizumab and Ustekinumab Therapy in IBD PatientsECCO'25Year: 2025
Authors: Saliutina, M.(1,2)*;Cancino, C.(1,2);Juhran, K.S.(1,2);Fritz, K.(1,2);Eleftheriadou, A.M.(1);Velasco Blazquez, L.(1,2);Konopka, A.(1,2);Luo, Y.(1,2);Weidinger, C.(1);Sonnenberg, E.(1);Siegmund, B.(1);Hegazy, A.N.(1,2);
(1)Charité-Universitätsmedizin Berlin, Department of Gastroenterology- Infectious Diseases and Rheumatology, Berlin, Germany;(2)Deutsches Rheumaforschungszentrum Berlin DRFZ, An Institute of the Leibniz Association, Berlin, Germany; Charité IBD Group
